| Functionally defined therapeutic targets in diffuse intrinsic pontine glioma CS Grasso, Y Tang, N Truffaux, NE Berlow, L Liu, MA Debily, MJ Quist, ... Nature medicine 21 (6), 555-559, 2015 | 631 | 2015 |
| Group, one-on-one, or internet? Preferences for mindfulness meditation delivery format and their predictors H Wahbeh, MN Svalina, BS Oken Open medicine journal 1, 66, 2014 | 142 | 2014 |
| The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma N Bharathy, NE Berlow, E Wang, J Abraham, TP Settelmeyer, JE Hooper, ... Science signaling 11 (557), eaau7632, 2018 | 59 | 2018 |
| IGF1R as a key target in high risk, metastatic medulloblastoma MN Svalina, K Kikuchi, J Abraham, S Lal, MA Davare, TP Settelmeyer, ... Scientific reports 6 (1), 27012, 2016 | 34 | 2016 |
| Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma N Bharathy, MN Svalina, TP Settelmeyer, MM Cleary, NE Berlow, ... Oncotarget 8 (38), 62976, 2017 | 24 | 2017 |
| IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma NE Berlow, MN Svalina, MJ Quist, TP Settelmeyer, V Zherebitskiy, ... PloS one 13 (4), e0193565, 2018 | 23 | 2018 |
| Preclinical rationale for entinostat in embryonal rhabdomyosarcoma N Bharathy, NE Berlow, E Wang, J Abraham, TP Settelmeyer, JE Hooper, ... Skeletal Muscle 9, 1-10, 2019 | 22 | 2019 |
| Volasertib preclinical activity in high-risk hepatoblastoma D Kats, CA Ricker, NE Berlow, B Noblet, D Nicolle, K Mevel, ... Oncotarget 10 (60), 6403, 2019 | 21 | 2019 |
| Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma NE Berlow, R Rikhi, M Geltzeiler, J Abraham, MN Svalina, LE Davis, ... BMC cancer 19, 1-23, 2019 | 18 | 2019 |
| Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species LE Davis, S Jeng, MN Svalina, E Huang, J Pittsenbarger, EL Cantor, ... Oncotarget 8 (44), 76241, 2017 | 15 | 2017 |
| YAPping about differentiation therapy in muscle cancer MN Svalina, C Keller Cancer cell 26 (2), 154-155, 2014 | 13 | 2014 |
| EphB4/EphrinB2 therapeutics in rhabdomyosarcoma ME Randolph, MM Cleary, Z Bajwa, MN Svalina, MC Young, A Mansoor, ... PLoS One 12 (8), e0183161, 2017 | 12 | 2017 |
| Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma K Kikuchi, E Taniguchi, HIH Chen, MN Svalina, J Abraham, ET Huang, ... Skeletal Muscle 3, 1-15, 2013 | 11 | 2013 |
| Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma D Beltrán, ME Anderson, N Bharathy, TP Settelmeyer, MN Svalina, ... Skeletal muscle 9, 1-10, 2019 | 10 | 2019 |
| NFκB signaling in alveolar rhabdomyosarcoma MM Cleary, A Mansoor, T Settelmeyer, Y Ijiri, KJ Ladner, MN Svalina, ... Disease models & mechanisms 10 (9), 1109-1115, 2017 | 8 | 2017 |
| Basolateral amygdala hyperexcitability is associated with precocious developmental emergence of fear-learning in Fragile X Syndrome MN Svalina, CA Cea-Del Rio, JK Kushner, A Levy, SM Baca, ... Journal of Neuroscience 42 (38), 7294-7308, 2022 | 6 | 2022 |
| Hyperexcitability and loss of feedforward inhibition contribute to aberrant plasticity in the Fmr1KO amygdala MN Svalina, EM Guthman, CA Cea-Del Rio, JK Kushner, SM Baca, ... Eneuro 8 (3), 2021 | 6 | 2021 |
| Murine model of hepatic breast cancer R Rikhi, EM Wilson, O Deas, MN Svalina, J Bial, A Mansoor, S Cairo, ... Biochemistry and biophysics reports 8, 1-5, 2016 | 5 | 2016 |
| Group, one-on-one, or internet? Preferences for mindfulness meditation delivery format and their predictors. Open Med J. 2014; 1: 66–74. doi: 10.2174/1874220301401010066 H Wahbeh, MN Svalina, BS Oken | 5 | |
| MEK1/2 in Rhabdomyosarcoma KA Crawford, MM Cleary, CA Ricker, MN Svalina, JF Shern, J Khan, ... bioRxiv, 629766, 2019 | 2 | 2019 |
